Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ranmark

- PMLiVE

Takeda’s dengue vaccine seems safe with no prior virus exposure

Appears unaffected by serious safety issue affecting Sanofi rival

- PMLiVE

Takeda divests over-the-counter and prescription drugs to Stada for $660m

Japanese pharma said it has plans to divest $10bn in non-core assests

Daiichi Sankyo logo

Daiichi files lawsuit with Seattle over ADCs, including AZ-partnered DS-8201

Dispute covers multiple drugs in Daiichi's antibody-drug conjugates pipeline

- PMLiVE

GSK boosts outlook thanks to strong respiratory and vaccine sales

Key Q3 drivers include Shingrix vaccine and asthma drug Nucala

- PMLiVE

GSK takes new-class antibiotic into phase 3 for serious infections

Could provide a much-needed option for treatment-resistant infections

- PMLiVE

Astellas stays ahead of its FLT3 rivals with EU nod for Xospata

Approval comes after an accelerated review of the drug

- PMLiVE

GSK gets FDA okay for wider use of PARP drug Zejula

New approval should help it gain some ground from AZ's rival Lynparza

- PMLiVE

AZ and Daiichi get speedy review for rival to Roche’s HER2 drugs

Could add to AZ's portfolio of emerging cancer drugs

- PMLiVE

Takeda offloads select portfolio to Acino ahead of Shire takeover

Hopes to reduce debt before acquistion completion

- PMLiVE

Avanir’s week goes from bad to worse with Alzheimer’s stumble

Suffers a blow as second phase 3 trial misses the mark

- PMLiVE

GSK’s Zejula challenges AZ/Merck’s Lynparza in PARP inhibitor category

New data in ovarian cancer creates potential for market battle

- PMLiVE

GSK and Apotex join generic Zantac recalls as carcinogen concerns mount

Novartis’ generic unit Sandoz halted distribution last week

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links